Graviti Pharmaceuticals
Modified-release tablet

Cardigrav XR

Metoprolol Succinate

25 mg50 mg100 mg
Cardigrav XR modified-release tablet — Metoprolol Succinate
Indications

Hypertension, angina pectoris and stable symptomatic chronic heart failure.

Composition

Each extended-release tablet contains Metoprolol Succinate equivalent to Metoprolol Tartrate.

How we make it

Multiparticulate pellet-in-tablet system delivering a 24-hour release profile with low inter-batch variance.

This information is intended for healthcare professionals and trade partners. The brand name applies to Graviti's own branded generics range in India; in other markets the same formulation is supplied as a generic under our filings or a partner label. Prescribing information, registration status and pack availability vary by market. Medicines should be used only under qualified medical supervision.

Graviti line producing Cardigrav XR

Cardigrav XR — made to the same standard as every Graviti batch.